Siplizumab vs Rabbit ATG kidney transplant study

This ClinicalTrials.gov record registers a Phase 2/3 randomized controlled trial (NCT07508787) evaluating siplizumab versus rabbit anti-thymocyte globulin (ATG) for induction immunosuppression in kidney transplant recipients. The study appears to be an active interventional trial examining safety and efficacy outcomes with approximately 176 participants receiving either siplizumab or rabbit ATG as part of their immunosuppressive regimen.

Clinical trial sponsors and investigators should ensure the trial is conducted according to the registered protocol, with appropriate IRB oversight and FDA reporting obligations. Participants are being recruited at participating transplant centers. Results will be posted to ClinicalTrials.gov upon trial completion per FDAAA 801 requirements.